MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D....
-
Upload
edith-dennis -
Category
Documents
-
view
213 -
download
0
Transcript of MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D....
![Page 1: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/1.jpg)
MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING
SEDATING MEDICATIONS
Gary G. Kay, Ph.D.Associate Clinical Professor of Neurology
Director, Neuropsychology DivisionGeorgetown University School of Medicine
Washington, DC
&President
Washington Neuropsychological InstituteWashington, DC
FDA/NTSB PUBLIC HEARING: Transportation Safety and Potentially Sedating or Impairing Medications, November 14-15, 2001, Washington, DC
![Page 2: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/2.jpg)
Definition of Sedation
Depression of brain functioning by a
medication, manifested by: sleepiness, drowsiness, fatigue
slowed brain activity
reduced wakefulness
impaired performance
![Page 3: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/3.jpg)
Evaluating Sedation
Self-report measures
Physiologic measures
Performance measures
![Page 4: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/4.jpg)
Evaluating Sedation
Self-report measures Diary Cards
Rating Scales, Mood Inventories
Visual Analog Scales
Personal Data Assistant (Palm Pilot)
Prescription Event Monitoring
![Page 5: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/5.jpg)
Evaluating Sedation:Self-Report Measures
Problems with self-report Subjectivity Self-report bias Validity – Self-report frequently is not consistent with
physiological and performance evidence of sedation
![Page 6: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/6.jpg)
Cognitive Performance:Changes From Baseline in Non-Sleepy Patients
Day 1 Treatment EffectsDay 1 Treatment Effects
Kay, et al. AAAAI. 1999.
.4
.2
0
-2
-.4
-.6
-.8
-1.0
Factor
Divided attention/working memory
Vigilance
SpeedFac
tor
Sco
re (
mea
n c
han
ge
fro
m b
asel
ine)
Diphenhydramine Loratadine Placebo
![Page 7: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/7.jpg)
Evaluating Sedation:Physiologic Measures
EEG (e.g., continuous EEG for microsleeps)
Evoked potentials (e.g., P300)
Functional brain imaging (e.g., PET and fMRI)
Multiple sleep latency test (MSLT)
Activity monitors (e.g., wrist actigraph)
![Page 8: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/8.jpg)
MULTIPLE SLEEP LATENCY TESTAVERAGE NUMBER OF MINUTES TO FALL ASLEEP
0
2
4
6
8
10
12
DAY 2
Min
ute
s Placebo
CP 8mg
CP 12mg
p=.003p=.007
![Page 9: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/9.jpg)
SELF-REPORTED SLEEPINESSSTANFORD SLEEPINESS SCALE (8:30 AM TEST)
1
2
3
4
5
6
7
DAY 2
Inc
rea
sin
g S
lee
pin
es
s
Placebo
CP 8mg
CP 12mg
p=.04
![Page 10: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/10.jpg)
Functional MRI:Mental Arithmetic Test
Starbuck, et al. AAAAI. 1998.
Change From Baseline to Day 3 of Change From Baseline to Day 3 of AMAM--PMPM Dosing: Dosing:Frontoparietal Brain ActivationFrontoparietal Brain Activation
P = .009
P = .002
-100
-50
0
50
100
150
Pix
el a
ctiv
atio
n
Placebo
CP 8 mg/TF
CP 12 mg/TF
![Page 11: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/11.jpg)
Evaluating Sedation:Performance Measures
Simulation (e.g., driving, flying)
Cognitive testing*
Psychomotor testing*
*Computer-based cognitive and psychomotor
testing is employed by pharmaceutical industry
and FDA to assess CNS effects
![Page 12: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/12.jpg)
Comparison of the Acute and Steady-State Effects of Loratadine, Diphenhydramine, and Placebo
Assess the cognitive, psychomotor, and subjective effects of these antihistamines.
Determine the relationship between self-reported sedation and cognitive performance.
Kay, et al. Arch Intern Med. 1997.
Subjects (N=98) were randomly assigned to one of the 3 treatment groups: 10 mg loratadine 50 mg diphenhydramine on Day 1, followed
by 25mg 4x/day on Days 2-5 placebo
![Page 13: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/13.jpg)
Day 1:Change in Factor Scores
Fac
tor
sco
res,
z-s
core
un
its
Betterfunctioning
Poorerfunctioning
Kay, et al. Arch Intern Med. 1997.
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
Mood &sedation Speed
Workingmemory
Dividedattention
DiphenhydramineLoratadinePlacebo
![Page 14: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/14.jpg)
Vigilance: Continuous Performance Test Accuracy
Day 1 ResultsDay 1 Results
Kay, et al. Arch Intern Med. 1997.
84
86
88
90
92
94
96
98
100
CP
T a
ccu
racy
, %
DiphenhydramineLoratadinePlacebo
![Page 15: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/15.jpg)
VIGILANCE: Capacity to sustain attention under conditions of minimal arousal (e.g., monotonous tasks).
DIVIDED ATTENTION: Ability to perform simultaneous mental activities; also referred to as dual tasking.
WORKING MEMORY: Ability to hold information temporarily in one’s head for purposes of using the information in a calculation, or other mental activity.
CRITICAL COGNITIVE DOMAINS FOR DEMONSTRATING SEDATION
![Page 16: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/16.jpg)
Consistent Neuropsychological Findings with Sedating Medications
Tests of vigilance (i.e., lapses of attention) appear to be the most sensitive measures for detecting the sedation effects that may contribute to accidents.
Psychomotor effects (i.e., disruption of tracking) appear to persist (for weeks) after adaptation has occurred to cognitive effects.
![Page 17: MEASURING IMPAIRMENT: VALIDATED TEST METHODS FOR ASSESSING SEDATING MEDICATIONS Gary G. Kay, Ph.D. Associate Clinical Professor of Neurology Director,](https://reader036.fdocuments.us/reader036/viewer/2022082819/56649e225503460f94b0e6ed/html5/thumbnails/17.jpg)
Summary
Sedating medications can cause impairment in the absence of sleepiness.
Sedating (OTC and Rx) medications don’t only cause sleepiness. They impair alertness, cognitive and psychomotor functioning.
Sedating effects may carry over to the following day even when medications are taken at night.
Vigilance, divided attention, and working memory are especially vulnerable to sedating medications
Assessment of sedation effects (and consumer/ prescriber information about sedation) should be based on more than self-report findings.